Cost-effectiveness of clopidogrel in STEMI patients in the Netherlands: a model based on the CLARITY trial

References

• Mehta SR, Yusuf S, Peters RGJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358:527-33
   PubMed Web of Science ®Google Scholar
• Steinhubl SR, Berger PB, Mann JT, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288:2411-20
   PubMed Web of Science ®Google Scholar
• Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Cannon CP, Gibson M, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005;352:1179-89
   PubMed Web of Science ®Google Scholar
• COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005;366:1607-21
   PubMed Web of Science ®Google Scholar
• Berg J, Lindgren P, Spiesser J, et al. Cost-effectiveness of clopidogrel in myocardial infarction with ST-segment elevation: a European model based on the CLARITY and COMMIT trials. Clin Ther 2007;29:1184-202
   PubMed Web of Science ®Google Scholar
• Swedish National Board of Health and Welfare. Hospital discharge register 1995–2003. 2003
   Google Scholar
• Swedish National Board of Health and Welfare. Cause of death register 1995–2003. 2003
   Google Scholar
• World Health Organization. Highlights on health in Sweden. 2004
   Google Scholar
• World Health Organization. Highlights on health in the Netherlands. 2004
   Google Scholar
• Centraal Bureau voor de Statistiek. Time series labour force by sex. 2006
   Google Scholar
• Jacob-Tacken KHM, Koopmanschap MA, Meerding WJ, et al. Correcting for compensating mechanisms related to productivity costs in economic evaluations of health care programmes. Health Econ 2004;14:435-43
   Web of Science ®Google Scholar
• Burstrom K, Johannesson M, Diderichsen F. Health-related quality of life by disease and socio-economic group in the general population in Sweden. Health Policy 2001;55:51-69
   PubMed Web of Science ®Google Scholar
• Hiatt MD. Thrombolytic therapy with streptokinase and tissue plasminogen activator in a patient with suspected acute myocardial infarction: a decision analysis. Cardiology 1999;91:243-9
   PubMed Web of Science ®Google Scholar
• Mark D, Hlatky M, Califf R, et al. Cost-effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 1995;332:1418-24
   PubMed Web of Science ®Google Scholar
• Tsevat J, Goldman L, Soukup JR, et al. Stability of time–tradeoff utilities in survivors of myocardial infarction. Med Decis Making 1993;13:161-5
   PubMed Web of Science ®Google Scholar
• Hallan S, Asberg A, Indredavik B, et al. Quality of life after cerebrovascular stroke: a systematic study of patients' preferences for different functional outcomes. J Intern Med 1999;246:309-16
   PubMed Web of Science ®Google Scholar
• Lee TT, Solomon N, Heidenreich PA, et al. A cost-effectiveness of screening for carotoid stenosis in asymptomatic persons. Ann Intern Med 1997;126:337-46
   PubMed Web of Science ®Google Scholar
• College voor Zorgverzekeringen. Dutch guidelines for pharmacoeconomic research. Amstelveen: College voor Zorgverzekeringen, 1999
   Google Scholar
• CURE Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502
   PubMed Web of Science ®Google Scholar
• College voor Zorgverzekeringen. Medicijnkosten. 2006
   Google Scholar
• Fox KM and EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-8
   PubMed Web of Science ®Google Scholar
• Levy E, Gabriel S, Dinet J. The comparative medical costs of atherothrombotic disease in European countries. Pharmacoeconomics 2003;21:651-9
   PubMed Web of Science ®Google Scholar
• College van Toezicht Sociale Verzekeringen. Bestanden ziekteverzium uit de diagnosestatistiek ziekengeldverzekering 1994. 1996
   Google Scholar
• van Exel NJA, Koopmanschap MA, van Wijngaarden JDH, et al. Costs of stroke and stroke services: determinants of patient costs and a comparison of costs of regular care and care organised in stroke services. Cost Eff Resour Alloc 2003;1
   Google Scholar
• Dutch Healthcare Insurance Board. Manual for costing research, unit costs and tariffs medical procedures. 2006
   Google Scholar
• CAPRIE Steering Committee. A randomised, blinded trial of Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE). Lancet 1996;348:1329-39
   PubMed Web of Science ®Google Scholar
• Steinhubl SR, Berger PB, Mann JT, et al. Clopidogrel for the reduction of events during observation. JAMA 2002;288:2411-20
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Fox KAA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006;354:1706-17
   PubMed Web of Science ®Google Scholar
• Zhang Z, Kolm P, Mosse F, et al. Long-term cost-effectiveness of clopidogrel in STEMI patients. Int J Cardiol 2008;135:353-60
   PubMed Web of Science ®Google Scholar
• Harland JO, Unwin N, Bhopal RS, et al. Low levels of cardiovascular risk factors and coronary heart disease in a UK Chinese population. J Epidemiol Community Health 1997;51:636-42
   PubMed Web of Science ®Google Scholar
• Woo KS, Chook P, Young RP, et al. New risk factors for coronary heart disease in Asia. Int J Cardiol 1997;62:S39-S42
   PubMed Web of Science ®Google Scholar
• Brüggenjürgen B, Lindgren P, Ehlken B, et al. Long-term cost-effectiveness of clopidogrel in patients with acute coronary syndrome without ST-segment elevation in Germany. Eur J Health Econ 2007;8:51-7
   PubMed Web of Science ®Google Scholar
• Lamy A, Jönsson B, Weintraub WS, et al. The cost-effectiveness of the use of clopidogrel in acute coronary syndromes in five countries based upon the CURE study. Eur J Cardiovasc Prev Rehabil 2004;11:460-5
   PubMed Web of Science ®Google Scholar
• Lindgren P, Jönsson B, Yusuf S. Cost-effectiveness of clopidogrel in acute coronary syndromes in Sweden: a long-term model based on the cure trial. J Intern Med 2004;255:562-70
   PubMed Web of Science ®Google Scholar
• Berg J, Fidan D, Lindgren P. Cost-effectiveness of clopidogrel treatment in percutaneous coronary intervention: a European model based on a meta-analysis of the PCI-CURE, CREDO and PCI-CLARITY trials. Curr Med Res Opin 2008;24:2089-101
   PubMed Web of Science ®Google Scholar